Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-147-9 | CAS number: 10563-26-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral: 950 mg/kg bw < LD 50< 1397 mg/kg bw (Similar to OECD TG 401; BASF SE, 1977)
Acute dermal: LD 50 > 200 mg/kg bw (OECD 402; Air Products & Chemicals Inc, 2007)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable study report wich meets basic scientific principles, however with the following restriction: Minimal details on test animals were given.
- Principles of method if other than guideline:
- BASF Test:
Several groups of 5 rats were treated by gavage with suspensions of the test substance in 0.5% Carboxylmethyl cellulose (CMC) aqueous preparation. Group-wise documentation of clinical signs was performed over the 14-day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose. The clinical signs and findings were reported in summary form. - GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: males 202 g, females 170 g (mean)
- Diet: Altromin R 124 (Altromin GmbH, Lage) - Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Doses:
- 647, 950, 1397, 2043, 3002 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Statistics:
- Probit analysis was used for the determination of the LD50.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 1 140 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: 950 mg/kg bw < LD 50< 1397 mg/kg bw
- Mortality:
- 3002 and 2043 mg/kg bw: all animals died
1397 mg/kg bw: all male animals and 4/5 female animals died
950 mg/kg bw: 1/5 males died, all females survived
647 mg/kg bw: all animals survived - Clinical signs:
- other: Dyspnoea, poor general state, apathy, abdominal or lateral position, spastic gait, atonia, and diarrhoea were noted in the 1397, 2043 and 3002 mg/kg bw dose groups.
- Gross pathology:
- Necropsy findings of the animals that died comprised erythema of the intestinal mucosa, acute congestive hyperemia and dilatation of the heart, acute cachexia.
Reference
Dose (mg/kg bw)
|
Mortality Dead/Treated |
|||||||||
1 hour |
24 hours |
48 hours |
7 days |
14 days |
||||||
male |
female |
male |
female |
male |
female |
male |
female |
male |
female |
|
647 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
950 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
1/5 |
0/5 |
1/5 |
0/5 |
1397 |
0/5 |
0/5 |
1/5 |
2/5 |
3/5 |
2/5 |
5/5 |
4/5 |
5/5 |
4/5 |
2043 |
0/5 |
0/5 |
5/5 |
5/5 |
5/5 |
5/5 |
5/5 |
5/5 |
5/5 |
5/5 |
3002 |
1/5 |
0/5 |
5/5 |
5/5 |
5/5 |
5/5 |
5/5 |
5/5 |
5/5 |
5/5 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 140 mg/kg bw
- Quality of whole database:
- Acceptable, well-documented study report.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 200 mg/kg bw
- Quality of whole database:
- Acceptable, well documented study report.
Additional information
Oral exposure
The potential of the test substance (purity >97%) to induce acute oral toxicity was evaluated in male and female SD rats in a test protocol conducted similar to the OECD TG 401 with acceptable deviations (BASF SE, 1977). Groups of 5 rats per dose were treated by gavage with suspensions of the test substance in 0.5% Carboxylmethyl cellulose (CMC) aqueous preparation at dose levels of 647, 950, 1397, 2043, and 3002 mg/kg bw. Group-wise documentation of clinical signs was performed over the 14-day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose. The clinical signs and findings were reported in summary form. All animals died in the 2043 and 3002 mg/kg bw dose groups within 24 hours , 5/5 males and 4/5 females in the 1397 mg/kg bw dose group within 7 days, and 1/5 males in the 950 mg/kg bw dose group within 7 days. No animal died in the low dose group. Clinical signs included dyspnoea, poor general state, apathy, abdominal or lateral position, spastic gait, atonia, and diarrhea, generally noted in the 1397, 2043 and 3002 mg/kg bw dose groups. Body weights generally decreased during the course of the study. Erythema of the intestinal mucosa, acute congestive hyperemia, dilatation of the heart, and acute cachexia were generally observed at necropsy in the animals that died.
Therefore, based on the results of the study, an acute oral LD50 > 950 mg/kg bw and < 1397 mg/kg bw was assumed after administration to rats.
Dermal exposure
The potential of the test substance to induce acute dermal toxicity was evaluated in 2 studies (2 batches were tested) in a test protocol conducted according to the OECD TG 402 (Air Products & Chemicals, Inc., 2007) in healthy male and female New Zealand White rabbits (2 males and 3 females in the first study [Project number MB 07-16376.02, TS purity = 83.4%] and in 3 males and 2 females in the second study [Project number MB 07-16377.02, TS purity = 92.2%]). The animals were dosed with a unique dose of 200 mg/kg bw under semiocclusive coverage for 24 hours, and observed for toxicity and pharmacological effects at 1, 2 and 4 hours post-dose and once daily for 14 days. All animals were also observed twice a day for mortality and body weights were recorded pretest, weekly and at termination. At termination, all animals were examined for gross pathology and abnormal tissues were preserved in 10% neutral buffered formalin for possible future histological examination. All Animals survived the 200 mg/kg bw dermal application of the test substance. Only one animal of the first study appeared lethargic on the day of treatment (Day 0). There were no further adverse clinical effects and body weight changes were normal in both studies. Severe dermal effects (necrosis) were observed after 24 hours, on days 11 and 14, and at necropsy. No further adverse effects were observed at necropsy. Therefore, based on the observed results, the dermal LD50 of test substance after acute dermal application to rabbits appeared to be greater than 200 mg/kg bw.
The acute dermal toxicity of the test substance (TS purity >97%) was also evaluated in rabbits in a test protocol conducted similar to the OECD TG 402 with acceptable deviations (BASF SE, 1977). 3 male and 3 female rabbits were treated with 190 mg/kg bw test substance applied to a haven skin site on their back for 24 h under occlusive conditions. The animals were observed for 14 days for mortality and clinical signs of toxicity, and those animals that died during the course of the study were submitted to necropsy. Survived animals were also subjected to gross-pathological examination. One male animal was found dead within 48 hours after treatment and a total of 3 animals (2 males and 1 female) died up to the end of the observation period. Clinical signs of toxicity included apathy, dispnoea, cyanosis, tremor, piloerection, blood-coloured urine with hematoma and poor general state. Local signs of irritation included erythema, edema, necrosis and desquamation observed in all animals. Based on the results of the study an acute dermal LD50 of approx. 190 mg/kg bw after administration of test substance to rabbits.
Taken together all data the acute dermal LD50 is estimated to be greater than 200 mg/kg bw.
Inhalation exposure
No reliable data available. One disregarded study done by BASF in 1977 is available.
The animals were exposed to the saturated vapours generated from a test substance with very low vapour pressure. The nominal concentration and saturated concentration (calculated) was approximately 0 mg/L indicating that the animals were not exposed to the vapours. Analytical verification of the test atmosphere was not performed. Keeping in view these methodological deficiencies, the study was considered to be not reliable for the assessment.
Justification for selection of acute toxicity – oral endpoint
Only one study available.
Justification for selection of acute toxicity – dermal endpoint
Key study
Justification for classification or non-classification
Based on the oral LD50, the test substance has to be classified according to EU Annex VI of directive 67/548/EEC (Xn, R22) and 1272/2008/EEC (Cat 4) for the oral route.
Based on the dermal LD50, the test substance has to be classified according to EU Annex VI of directive 67/548/EEC (T, R24) and 1272/2008/EEC (Cat 3) for the dermal route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.